Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) EBT (2020 - 2025)

Historic EBT for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to -$52.8 million.

  • Rhythm Pharmaceuticals' EBT fell 2002.5% to -$52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$191.9 million, marking a year-over-year increase of 2570.43%. This contributed to the annual value of -$260.3 million for FY2024, which is 4135.59% down from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' EBT stood at -$52.8 million, which was down 2002.5% from -$46.3 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' EBT peaked at $65.8 million during Q1 2021, and registered a low of -$141.1 million during Q1 2024.
  • In the last 5 years, Rhythm Pharmaceuticals' EBT had a median value of -$44.1 million in 2021 and averaged -$44.4 million.
  • In the last 5 years, Rhythm Pharmaceuticals' EBT skyrocketed by 29247.16% in 2021 and then plummeted by 17988.78% in 2022.
  • Quarter analysis of 5 years shows Rhythm Pharmaceuticals' EBT stood at -$50.9 million in 2021, then rose by 16.44% to -$42.5 million in 2022, then grew by 2.49% to -$41.4 million in 2023, then fell by 4.69% to -$43.4 million in 2024, then fell by 21.69% to -$52.8 million in 2025.
  • Its EBT was -$52.8 million in Q3 2025, compared to -$46.3 million in Q2 2025 and -$49.4 million in Q1 2025.